MannKind Corporation (NASDAQ: MNKD) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
MannKind Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.07, MannKind Corporation trades at 3.1x sales, with an EV/EBITDA of 246.1. Over the last twelve months it generated about $417M of revenue and a net loss of $76M. It runs a gross margin of 76.0%, an operating margin of -3.2% and a net margin of -18.1%. It shows return on equity of 139.4%, return on invested capital of -2.0% and a free cash flow yield of -6.0%. On the balance sheet: a debt-to-equity ratio of -11.63 and a current ratio of 2.22. Over the past 52 weeks the share price ranged from $2.23 to $6.51, with a beta of 1.09.
MannKind Corporation does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 7 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MannKind Corporation (MNKD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 36.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.40% / 30% · Interest income / Revenue 1.07% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 36.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.40% / 33% · Receivables / Mkt Cap (36m) 3.57% / 49% · Interest income / Revenue 1.07% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 36.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.40% / 33.33% · Receivables / Mkt Cap (24m) 3.57% / 33.33% · Interest income / Revenue 1.07% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 48.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 17.1% / 33.33% · Receivables / Avg Assets (4Q) 5.06% / 33.33% · Interest income / Revenue 1.07% / 5% | Fail |
| FTSE | Debt / Total Assets 58.4% / 33.33% · (Cash+ST Inv) / Total Assets 13.4% / 33.33% · (Cash+Recv) / Total Assets 19.0% / 33.33% · Interest income / Revenue 1.07% / 5% | Fail |
No. As of September 2026, MannKind Corporation (MNKD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MannKind Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 1.07% of each dividend: MannKind Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.